Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Molecular Cancer Therapeutics|July 2, 2014
Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib)Jessica J Huck, Mengkun Zhang, Jerome Mettetal, et al.
Molecular Cancer Therapeutics|August 21, 2010
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamicsTeresa Macarulla, Andres Cervantes, Elena Elez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2011
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assaysMark G Manfredi, Jeffrey A Ecsedy, Arijit Chakravarty, et al.
The AAPS Journal|January 30, 2015
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscapeEdgar Schuck, Tonika Bohnert, Arijit Chakravarty, et al.
Cancer Research|December 15, 2010
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinaseArijit Chakravarty, Vaishali Shinde, Josep Tabernero, et al.
Pageof 5